COVID-19 treatment protocol in Sri Lanka

$0 $500 $1,000+ Efficacy vs. cost for COVID-19 treatment protocols c19early.org November 2025 Sri Lanka United Kingdom Russia USA Sudan Angola Colombia Kenya Mozambique Pakistan Argentina Vietnam Peru Philippines Spain Brazil Italy France Japan China Uzbekistan Nepal Iran Ghana Mexico South Korea Germany Saudi Arabia Algeria Morocco Yemen Poland India DR Congo Madagascar Thailand Uganda Venezuela Nigeria Egypt Bolivia Taiwan Zambia Fiji Bosnia-Herzegovina Bulgaria Greece Slovakia Singapore Iceland New Zealand Tajikistan Czechia Mongolia Israel Trinidad and Tobago Hong Kong North Macedonia Belarus Qatar Panama Serbia CAR Sri Lanka favored low-cost treatments.The average efficacy of treatments was moderate.Low-cost treatments improve early treatment, andprovide complementary/synergistic benefits. More effective More expensive 75% 50% 25% ≤0%
$0 $500 $1,000+ Efficacy vs. cost for COVID-19treatment protocols worldwide c19early.org November 2025 Sri Lanka United Kingdom Russia USA Sudan Angola Colombia Kenya Mozambique Pakistan Argentina Vietnam Peru Philippines Spain Brazil Italy France Japan China Uzbekistan Nepal Iran Ghana Mexico South Korea Germany Saudi Arabia Algeria Morocco Yemen Poland India DR Congo Madagascar Thailand Uganda Venezuela Nigeria Egypt Bolivia Taiwan Zambia Fiji Bulgaria Greece Slovakia Singapore New Zealand Tajikistan Malawi Czechia Mongolia Israel Trinidad and Tobago North Macedonia Belarus Qatar Panama Serbia Syria Sri Lanka favored low-cost treatments.The average efficacy was moderate.Low-cost protocols improve early treatment,and add complementary/synergistic benefits. More effective More expensive 75% 50% 25% ≤0%
Countries adopted very different treatment protocols for COVID-19. Some countries preferred novel high-profit treatments, while others also used many low-cost treatments. Low-cost non-prescription treatments can greatly increase treatment—especially early treatment—due to lower barriers to access, and research shows complementary and synergistic benefits with many treatments1-17.
The plot shows the average efficacy and cost of approved treatments in each country. Actual usage varied significantly from official protocols in many regions. Top countries by population are shown where space precludes showing all country names.
Submit updates or corrections.
References